100 Migraine Drugs, A to Z: fluoxetine

January 9, 2019

Antidepressants are widely used for the preventive treatment of migraine headaches. However, some types of antidepressants are better for this purpose than other. Fluoxetine (Prozac, Sarafem) was the first drug in the family of selective serotonin reuptake inhibitors (SSRIs) to be introduced in 1986. This category of antidepressants became very popular not because these drugs were more effective than the older antidepressants, but because they had fewer side effects.

Because tricyclic antidepressants were known to relieve pain and prevent migraine headaches, when the SSRIs became available, they were also studied for various painful conditions.

Small studies suggested that fluoxetine and similar drugs may be effective for the prevention of migraines. Here is another such small study. However, larger and scientifically more rigorous trials showed no effect of fluoxetine on migraines.

Despite this lack of scientific evidence, SSRIs (escitalopram, or Lexapro, paroxetine, or Paxil, sertraline, or Zoloft) are often prescribed for migraines and some migraine sufferers report feeling better on these drugs. One possible explanation is the placebo effect, but it is more likely to be due to the relief of anxiety and depression with some secondary improvement of migraine headaches. In case of tricyclic and some other antidepressants, their pain relieving properties are independent of their effect on depression.

While SSRIs have fewer side effects than many other antidepressants, they also can cause nausea, dizziness, insomnia, loss of libido, inability to reach an orgasm, and other unpleasant symptoms.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe